

	Inpatient Claim - Facility Reporting and Payment Implications ¹			Outpatient Claim - Facility Reporting and Payment Implications					Physician Claim - Professional Services Reporting and Payment Implications			
	ICD-10-PCS Codes	Revenue Codes for Charges ²	Description	CPT/HCPCS Codes	Revenue Codes for Charges ²	Description	Medicare Payment Implications	Commercial Payment Implications	CPT/HCPCS Codes	Description	Medicare Considerations and Payment Implications	Commercial Payment Implications
Coding Options for Reporting Administration of Autologous CAR-T	XW033C7 or XW043C7	0874	Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein (or Central) Percutaneous Approach, New Technology Group 7 (Used for an autologous CAR-T product, such as those currently under trial, where there is no product-specific ICD-10-PCS code to describe the product)	0540T	0874	Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous	OPPS Indicator = "S" ("significant procedure") Placed in APC 5694 While assigned a payment rate by Medicare, providers should still reach out to their MACs to confirm the code will be allowed/recognized, as the MAC may have a local policy that limits usage or applies edits to Category III codes.	Providers should contact their commercial payers and share this information to ensure the code is accepted as part of their contract	0540T	Chimeric antigen receptor T-cell (CAR-T) administration, autologous	Recognized as a carrier priced service as designated by status code "C" in the MPFS. Category III codes are manually priced by the MAC based on a written explanation of the service and usually a code provided by the clinician as a reasonable proxy to cross-walk to for payment purposes, CPT code 38241 is a possible cross-walk code choice if the clinician feels CAR-T administration requires similar resource utilization as autologous hematopoietic progenitor cell (HPC) transplantation; if not, then a different code/service will need to be provided to the MAC. Despite being deemed carrier priced, providers will need to reach out to their MACs to confirm the code will be allowed/recognized, as the MAC may have a local policy that that limits usage or applies edits to Category III codes.	Providers should contact their commercial payers and share this information to ensure the code is accepted as part of their contract
	XW033I7 or XW043I7		Introduction of Tisagenlecleumab Immunotherapy into Peripheral Vein (or Central), Percutaneous Approach, New Technology Group 7									
	XW033H7 or XW043H7		Introduction of Axicabtagene Ciloleucele Immunotherapy into Peripheral Vein (or Central), Percutaneous Approach, New Technology Group 7									
	XW033M7 or XW043M7		Introduction of Brexucabtagene Autoleucele Immunotherapy into Peripheral Vein (or Central), Percutaneous Approach, New Technology Group 7									
	XW033N7 or XW043N7		Introduction of Lisocabtagene Maraleucele Immunotherapy into Peripheral Vein (or Central), Percutaneous Approach, New Technology Group 7									
	XW033K7 or XW043K7		Introduction of Idecabtagene Vicleucele Immunotherapy into Peripheral Vein (or Central), Percutaneous Approach, New Technology Group 7									
	XW033A7 or XW043A7		Introduction of Ciltacabtagene Autoleucele into Peripheral Vein (or Central), Percutaneous Approach, New Technology Group 7									
Coding Options for Reporting Administration of Allogeneic CAR-T	XW033G7 or XW043G7	0874	Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein (or Central), Percutaneous Approach, New Technology Group 7 (Used to describe the administration of any allogeneic CAR-T product)	Recommended: 38999 ³	0874	Unlisted procedure, hemic or lymphatic system	Medicare typically assigns unlisted codes to the lowest paying APC in the applicable APC range.	All payers and providers must follow HIPAA code sets and guidelines. AMA/CPT codes and guidelines are part of HIPAA transaction code sets. Because 38999 is a non-specific CPT code, payers may request additional information. Providers should refer to their contracts.	Recommended: 38999 ³	Unlisted procedure, hemic or lymphatic system	Medicare typically assigns unlisted codes to the lowest paying APC in the applicable APC range.	All payers and providers must follow HIPAA code sets and guidelines. AMA/CPT codes and guidelines are part of HIPAA transaction code sets. Because 38999 is a non-specific CPT code, payers may request additional information. Providers should refer to their contracts.

¹ For Medicare, MS-DRG 018 is assigned for inpatient CAR-T administration based on reporting a CAR-T administration ICD-10-PCS procedure code. A payment adjustment will be applied to claims that group to MS-DRG 018 and include ICD-10-CM diagnosis code Z00.6 or when there is expanded access use of immunotherapy. However, when the provider incurs a cost for the CAR-T cell therapy product and the case involves a clinical trial of a different product, the payment adjustment will not be applied, and the provider will receive the full MS-DRG 018 payment. Providers will have to notify their MACs of these situations. To notify the MAC of a case where there was expanded access to CAR-T cell therapy products, after October 1, 2022, providers are instructed to put condition code 90 on the claim. Prior to October 1, 2022, CMS had instructed providers to enter a Billing Note NTE02 "Expanded Acc Use" on the electronic claim 837 or add "Expanded Acc Use" in the remarks field on a paper claim (Form Locator 80). To notify the MAC of a case where the CAR-T cell therapy product is purchased in the usual manner, but the case involves a clinical trial of a different product (and ICD-10-CM diagnosis code Z00.6 on the claim), the provider may enter a Billing Note NTE02 "Off Prod Clin Trial" on the electronic claim 837 or a remark "Off Prod Clin Trial" on a paper claim. Providers should consult the guidance released by CMS in Transmittal R138000C effective Oct 1, 2020. This can be found at: <https://www.cms.gov/medicare/coverage/determination-process/2020oct1> and the FY 2023 OPPS final rule information on condition code 90 at: <https://www.federalregister.gov/documents/2022/10/20/2022-10452-opps>. For commercial payer or State Medicaid payment, providers need to check their contracts or agreements.

² Hospital should report a procedure charge for the cell administration whether inpatient at the bedside or outpatient

Note 1: Do not report unlisted code 38999 for cell collection or cell processing services for autologous CAR-T therapy (for allogeneic, see ³ below) New that more specific codes are available - see the National Correct Coding Initiative (NCCI) edit manual

Note 2: New revenue codes have been placed since April 1, 2023 for reporting cell collection and cell processing services; see the National Ambulatory Billing Committee (NABC) manual: <http://www.nabc.org/publications/PCS%20Codes%20Changes%20August%202023.pdf>. All providers and payers have to use the new codes per the HIPAA transaction code set regulations.

³ Since there is no specific CPT code for allogeneic CAR-T administration, per AMA/CPT guidance, do not select a CPT code that merely approximates the service provided. If there are no codes that accurately identify the service being provided, report the service using the approximate unlisted procedure or service code. See Introduction section, "Instructions for the Use of the CPT Codebook", in American Medical Association (AMA), CPT Professional Edition 2021 code book, Chicago (IL): AMA, 2020.

DISCLAIMER: This information was obtained from third-party sources and is subject to change at any time without notice, including as a result of changes in coding, reimbursement, laws, regulations, rules, and policies. Content is informational only, and does not cover all situations or all payers' rules or policies. This document represents no promise or guarantee by ASTCT regarding coverage or reimbursement. The ultimate responsibility for coding and claims submissions lies with the physician, clinician, hospital, and/or other facility. Providers should consult their payers and check bulletins, manuals, program memoranda, and guidelines to ensure compliance with requirements.